[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-001", "question": "A 63-year-old man with ischemic cardiomyopathy (LVEF 20%) and NYHA class III symptoms despite guideline-directed therapy presents with increasing fatigue and abdominal swelling. BP is 88/54 mm Hg, HR 78/min, JVP 15 cm with prominent v waves, and there is a holosystolic murmur at the left lower sternal border that increases with inspiration. Echo shows severe functional tricuspid regurgitation with right atrial and RV dilation, TAPSE 1.0 cm, RV fractional area change 25%, PASP 42 mm Hg, and no significant left-sided valvular disease. Coronary anatomy is unchanged from prior and not revascularizable. He is in sinus rhythm and not a heart transplant candidate. After optimization of diuretics, he remains symptomatic. Which management strategy is most appropriate to improve outcomes?", "options": ["Surgical tricuspid valve replacement with bioprosthesis", "Catheter-based edge-to-edge tricuspid valve repair", "Isolated LV assist device implantation", "Upgrade to CRT-D with AV node ablation", "Intensification of neurohormonal blockade with sacubitril/valsartan uptitration"], "answer": "B", "answer_index": 1, "explanation": "In advanced HFrEF with severe secondary TR, RV dysfunction, and prohibitive surgical risk, transcatheter edge-to-edge tricuspid repair is preferred and has evidence for symptomatic and functional improvement versus medical therapy alone. Surgical replacement carries high perioperative mortality with poor RV reserve; isolated LVAD can worsen RV failure; CRT-D and further neurohormonal titration are unlikely to meaningfully reverse severe functional TR at this stage.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 63-year-old with severe ischemic HFrEF (LVEF 20%), NYHA III despite GDMT, low BP (88/54), severe functional TR with RA/RV dilation, reduced RV function (TAPSE 1.0 cm, FAC 25%), PASP only mildly–moderately elevated, no left-sided valve disease, not a transplant candidate, optimized diuretics but still symptomatic. These features imply advanced HF with significant secondary TR and high/prohibitive surgical risk, where a less invasive percutaneous strategy to treat TR is preferred for symptomatic and functional improvement.\\nChoice B (catheter-based edge-to-edge tricuspid repair) aligns with current data (eg, TRILUMINATE) showing improved symptoms/quality of life and is reasonable in high-risk surgical candidates.\\nA (surgical replacement) has high perioperative mortality with poor RV reserve and is typically avoided here. C (isolated LVAD) can exacerbate RV failure and is not clearly indicated without LVAD/Tx program context. D (CRT-D with AV node ablation) lacks indication (sinus rhythm, no LBBB/QRS data). E (further sacubitril/valsartan uptitration) is limited by hypotension and unlikely to reverse severe TR.\\nMain medical issue: outcome benefits of TEER are primarily symptomatic/functional, not clearly mortality, but still consistent with “improve outcomes.”\\nMinimal fix: Clarify “improve symptomatic and functional outcomes” instead of generic “outcomes.”\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 63-year-old with severe ischemic HFrEF (LVEF 20%), NYHA III despite GDMT, low BP (88/54), severe functional TR with RA/RV dilation, reduced RV function (TAPSE 1.0 cm, FAC 25%), PASP only mildly–moderately elevated, no left-sided valve disease, not a transplant candidate, optimized diuretics but still symptomatic. These features imply advanced HF with significant secondary TR and high/prohibitive surgical risk, where a less invasive percutaneous strategy to treat TR is preferred for symptomatic and functional improvement.\nChoice B (catheter-based edge-to-edge tricuspid repair) aligns with current data (eg, TRILUMINATE) showing improved symptoms/quality of life and is reasonable in high-risk surgical candidates.\nA (surgical replacement) has high perioperative mortality with poor RV reserve and is typically avoided here. C (isolated LVAD) can exacerbate RV failure and is not clearly indicated without LVAD/Tx program context. D (CRT-D with AV node ablation) lacks indication (sinus rhythm, no LBBB/QRS data). E (further sacubitril/valsartan uptitration) is limited by hypotension and unlikely to reverse severe TR.\nMain medical issue: outcome benefits of TEER are primarily symptomatic/functional, not clearly mortality, but still consistent with “improve outcomes.”\nMinimal fix: Clarify “improve symptomatic and functional outcomes” instead of generic “outcomes.”", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-002", "question": "A 41-year-old woman presents with progressive exertional dyspnea and chest tightness. She has no smoking history, takes combined oral contraceptives, and has a brother who died suddenly at 32. Exam shows a loud P2 and a systolic murmur that increases with inspiration. ECG shows right axis deviation and incomplete RBBB. Transthoracic echo reveals severe pulmonary hypertension with estimated PASP 80 mm Hg, normal LV, and RV hypertrophy with preserved function. V/Q scan is normal. Right-heart cath shows: RA 6 mm Hg, RV 90/6 mm Hg, PA 88/32 mm Hg (mean 52), PCWP 9 mm Hg, CI 2.1 L/min/m², PVR 10 Wood units. Acute vasoreactivity testing with inhaled nitric oxide reduces mPAP to 42 mm Hg with unchanged CI and PVR 8 Wood units. Genetic testing is pending. What is the most appropriate initial long-term therapy?", "options": ["High-dose amlodipine monotherapy", "Combination therapy with ambrisentan and tadalafil", "Intravenous epoprostenol monotherapy", "Riociguat monotherapy", "Warfarin with target INR 3.0-4.0"], "answer": "B", "answer_index": 1, "explanation": "She has idiopathic or heritable PAH (group 1) with high-risk features and a negative acute vasoreactivity test (insufficient mPAP reduction and no CI improvement), so calcium channel blocker therapy is contraindicated. Current guidelines favor initial oral combination therapy with an endothelin receptor antagonist and a PDE5 inhibitor (e.g., ambrisentan+tadalafil) for WHO FC II-III with preserved RV function; IV epoprostenol is reserved for higher-risk or rapidly progressive disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 41-year-old woman; no lung or left-heart disease; very high mPAP and PVR with normal PCWP; normal V/Q (ruling out CTEPH); RV hypertrophy with preserved function; suggestive of idiopathic/heritable PAH (Group 1). Functional status is implied as WHO FC II–III (progressive exertional dyspnea, not yet decompensated; RV function preserved). Acute vasoreactivity test is negative (mPAP drop <10 mm Hg and not to <40; no CI improvement), so high-dose CCBs are contraindicated. In current guidelines, initial oral combination with ERA + PDE5 inhibitor is recommended for FC II–III without severe RV failure, making option B the single best answer.\\nOther options: A (CCB) is inappropriate with negative vasoreactivity; C (IV epoprostenol) is typically reserved for highest-risk / decompensated patients; D (riociguat) is not first-line in this Group 1 setting and better suited to CTEPH; E (warfarin with high INR) is no longer standard and target range is incorrect.\\nMain medical issues: Minor—FC not explicitly stated but reasonably inferred.\\nMinimal fix: Explicitly state WHO functional class (e.g., “WHO FC III but hemodynamically stable with preserved RV function”).\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 41-year-old woman; no lung or left-heart disease; very high mPAP and PVR with normal PCWP; normal V/Q (ruling out CTEPH); RV hypertrophy with preserved function; suggestive of idiopathic/heritable PAH (Group 1). Functional status is implied as WHO FC II–III (progressive exertional dyspnea, not yet decompensated; RV function preserved). Acute vasoreactivity test is negative (mPAP drop <10 mm Hg and not to <40; no CI improvement), so high-dose CCBs are contraindicated. In current guidelines, initial oral combination with ERA + PDE5 inhibitor is recommended for FC II–III without severe RV failure, making option B the single best answer.\nOther options: A (CCB) is inappropriate with negative vasoreactivity; C (IV epoprostenol) is typically reserved for highest-risk / decompensated patients; D (riociguat) is not first-line in this Group 1 setting and better suited to CTEPH; E (warfarin with high INR) is no longer standard and target range is incorrect.\nMain medical issues: Minor—FC not explicitly stated but reasonably inferred.\nMinimal fix: Explicitly state WHO functional class (e.g., “WHO FC III but hemodynamically stable with preserved RV function”).", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-003", "question": "A 27-year-old man presents with a first generalized tonic-clonic seizure. MRI brain with and without contrast is normal. EEG shows rare generalized spike-and-wave discharges at 3-4 Hz with a photoparoxysmal response. Over the next month he has two more generalized tonic-clonic seizures, each preceded by brief myoclonic jerks on awakening. He drinks socially and works as a software engineer. He and his partner plan to conceive in the next year, and he wants to avoid cognitive side effects. Which antiepileptic monotherapy is most appropriate?", "options": ["Valproate", "Levetiracetam", "Carbamazepine", "Lamotrigine", "Topiramate"], "answer": "B", "answer_index": 1, "explanation": "This is juvenile myoclonic epilepsy with generalized tonic-clonic and myoclonic seizures plus characteristic EEG. While valproate is highly effective, its teratogenicity, metabolic effects, and cognitive risks make it less desirable in a young adult planning pregnancy with a partner and with concerns about adverse effects. Levetiracetam is effective for generalized epilepsies, has a favorable cognitive profile, and minimal drug interactions; carbamazepine can worsen generalized seizures, and lamotrigine/topiramate are less predictably effective for myoclonus.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 27-year-old with first generalized tonic-clonic seizure; normal MRI; EEG with generalized 3–4 Hz spike-and-wave and photoparoxysmal response; subsequent morning myoclonic jerks preceding GTCs → classic juvenile myoclonic epilepsy (JME), an idiopathic generalized epilepsy. Treatment should be broad-spectrum and effective for GTC and myoclonic seizures while minimizing cognitive adverse effects in a young adult planning conception with partner.\\nLevetiracetam is well-supported as effective monotherapy in JME, with favorable cognitive profile and minimal interactions, aligning with his priorities. Valproate is highly effective but relatively less desirable given teratogenicity (even though partner, not patient, would be pregnant) and metabolic/cognitive side effects; still, on modern boards, levetiracetam is a reasonable preferred first-line alternative in this exact context. Carbamazepine can exacerbate generalized/myoclonic seizures. Lamotrigine is less reliable for myoclonus and may exacerbate it. Topiramate can impair cognition and is not clearly superior to levetiracetam for JME.\\nMain medical issue: subtle—teratogenic concerns are indirect (partner pregnant), but preference and cognitive concerns support levetiracetam as best choice.\\nMinimal fix: Clarify rationale by stating “he wishes to avoid weight gain and teratogenic medications for a potential future pregnancy with his partner.”\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 27-year-old with first generalized tonic-clonic seizure; normal MRI; EEG with generalized 3–4 Hz spike-and-wave and photoparoxysmal response; subsequent morning myoclonic jerks preceding GTCs → classic juvenile myoclonic epilepsy (JME), an idiopathic generalized epilepsy. Treatment should be broad-spectrum and effective for GTC and myoclonic seizures while minimizing cognitive adverse effects in a young adult planning conception with partner.\nLevetiracetam is well-supported as effective monotherapy in JME, with favorable cognitive profile and minimal interactions, aligning with his priorities. Valproate is highly effective but relatively less desirable given teratogenicity (even though partner, not patient, would be pregnant) and metabolic/cognitive side effects; still, on modern boards, levetiracetam is a reasonable preferred first-line alternative in this exact context. Carbamazepine can exacerbate generalized/myoclonic seizures. Lamotrigine is less reliable for myoclonus and may exacerbate it. Topiramate can impair cognition and is not clearly superior to levetiracetam for JME.\nMain medical issue: subtle—teratogenic concerns are indirect (partner pregnant), but preference and cognitive concerns support levetiracetam as best choice.\nMinimal fix: Clarify rationale by stating “he wishes to avoid weight gain and teratogenic medications for a potential future pregnancy with his partner.”", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-004", "question": "A 55-year-old woman with a 10-year history of poorly controlled type 2 diabetes presents with episodic confusion, sweating, and palpitations occurring mostly late afternoon. Capillary glucose during an event is 38 mg/dL, resolving with IV dextrose. She takes metformin and basal insulin at night; CGM shows multiple daytime hypoglycemic episodes despite reduction in insulin dose. She denies sulfonylurea use or alcohol. Fasting lab evaluation during supervised 48-hour fast is terminated at plasma glucose 42 mg/dL: insulin 6 μU/mL (normal 2-10), C-peptide 0.1 ng/mL (low), beta-hydroxybutyrate undetectable, and sulfonylurea/meglitinide screen negative. CT of the pancreas is normal. What is the most likely diagnosis?", "options": ["Factitious hypoglycemia from exogenous insulin analog use", "Insulinoma with intermittent secretion", "Non-islet cell tumor hypoglycemia due to IGF-2 secretion", "Autoimmune insulin receptor activating antibody syndrome", "Post-bariatric surgery hyperinsulinemic hypoglycemia"], "answer": "A", "answer_index": 0, "explanation": "Low C-peptide with inappropriately normal insulin at hypoglycemia and absent ketones indicates exogenous insulin, which suppresses endogenous insulin/C-peptide and ketogenesis. Standard insulin immunoassays may underdetect some analogs, yielding low-normal levels; nonetheless, the mismatch of insulin, C-peptide, and ketones supports factitious insulin use rather than insulinoma or IGF-2-mediated hypoglycemia (which would show low insulin/C-peptide but also low ketones via IGF-2 effects).", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Recurrent symptomatic hypoglycemia with documented glucose 38–42 mg/dL; low C‑peptide (0.1 ng/mL) at time of hypoglycemia; insulin in the low-normal range (6 μU/mL) that is inappropriately non-suppressed at glucose 42 mg/dL; undetectable β-hydroxybutyrate (suppressed ketogenesis); negative sulfonylurea/meglitinide screen; normal pancreatic CT. She is on prescribed basal insulin, and factitious/excess exogenous insulin is compatible with these labs, especially given that some assays under-detect analogs.\\nMain logical issues: Minimal. The presence of prescribed basal insulin is a potential confound, but in a supervised fast with clear biochemical pattern (low C-peptide, inappropriately present insulin, suppressed ketones, negative sulfonylurea, no tumor on imaging), exogenous insulin is the single best explanation among options.\\nOther options: Insulinoma should have high insulin and C‑peptide; IGF‑2 tumor causes low insulin/C‑peptide and low ketones; insulin receptor activating antibodies cause hyperglycemia or require high insulin; post-bariatric hypoglycemia requires surgery history.\\nMain medical accuracy issues: None significant; explanation is aligned with current understanding of hypoglycemia evaluation.\\nMinimal fix: Explicitly state that insulin was measured with an assay that may under-detect analogs, clarifying why insulin is only low-normal rather than clearly elevated.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Recurrent symptomatic hypoglycemia with documented glucose 38–42 mg/dL; low C‑peptide (0.1 ng/mL) at time of hypoglycemia; insulin in the low-normal range (6 μU/mL) that is inappropriately non-suppressed at glucose 42 mg/dL; undetectable β-hydroxybutyrate (suppressed ketogenesis); negative sulfonylurea/meglitinide screen; normal pancreatic CT. She is on prescribed basal insulin, and factitious/excess exogenous insulin is compatible with these labs, especially given that some assays under-detect analogs.\nMain logical issues: Minimal. The presence of prescribed basal insulin is a potential confound, but in a supervised fast with clear biochemical pattern (low C-peptide, inappropriately present insulin, suppressed ketones, negative sulfonylurea, no tumor on imaging), exogenous insulin is the single best explanation among options.\nOther options: Insulinoma should have high insulin and C‑peptide; IGF‑2 tumor causes low insulin/C‑peptide and low ketones; insulin receptor activating antibodies cause hyperglycemia or require high insulin; post-bariatric hypoglycemia requires surgery history.\nMain medical accuracy issues: None significant; explanation is aligned with current understanding of hypoglycemia evaluation.\nMinimal fix: Explicitly state that insulin was measured with an assay that may under-detect analogs, clarifying why insulin is only low-normal rather than clearly elevated.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-005", "question": "A 49-year-old man with poorly controlled hypertension and obesity presents with sudden severe dyspnea and pleuritic chest pain. He is tachypneic, diaphoretic, BP 82/54 mm Hg, HR 128/min, SpO2 86% on non-rebreather. JVP is 12 cm, lungs are clear. Bedside echo shows a dilated RV with McConnell sign and septal flattening; there is no pericardial effusion. CTA confirms a massive saddle pulmonary embolism with bilateral lobar clot burden. While preparing for systemic thrombolysis, he becomes pulseless with PEA. After 10 minutes of ACLS with ongoing CPR and no ROSC, what is the most appropriate next step?", "options": ["Administer full-dose systemic alteplase as a bolus during CPR", "Initiate venoarterial extracorporeal membrane oxygenation (VA-ECMO) followed by catheter-directed thrombectomy", "Administer half-dose systemic alteplase and continue CPR for at least 30 minutes", "Terminate resuscitation efforts due to poor prognosis", "Perform emergency surgical pulmonary embolectomy without ECMO"], "answer": "B", "answer_index": 1, "explanation": "In massive PE with refractory cardiac arrest and no ROSC after high-quality ACLS, VA-ECMO can provide immediate circulatory support and oxygenation, serving as a bridge to definitive reperfusion (catheter-directed or surgical embolectomy). Evidence and expert consensus increasingly support ECMO plus mechanical thrombectomy over late systemic lysis in this setting; halving the alteplase dose or surgical embolectomy without circulatory support are less effective and more dangerous during ongoing arrest.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible; also partly U for guideline nuance)\\nVerdict on keyed answer: Not uniquely determinable\\n\\nKey stem clues: Massive saddle PE with shock then PEA arrest, 10 minutes of high-quality ACLS with ongoing CPR and no ROSC; CTA-confirmed PE; bedside echo with RV strain; no pericardial effusion; question asks “most appropriate next step.” Options contrast systemic thrombolysis during arrest vs VA‑ECMO + thrombectomy vs reduced-dose lysis vs stopping vs surgical embolectomy alone.\\n\\nMajor logical issue: Current ACLS/PE guidelines (AHA, ESC) explicitly state that for suspected/confirmed PE causing cardiac arrest, systemic thrombolysis during CPR is recommended/very reasonable. VA‑ECMO is recommended only where immediately available and usually as adjunct/bridge. Many centers cannot initiate ECMO promptly during arrest. Thus A (full-dose systemic alteplase during CPR) is strongly guideline-supported as the primary next step, whereas B is a reasonable but resource‑dependent advanced option. The stem gives no information about ECMO availability, making B not clearly superior to A. Hence at least A and B are defensible.\\n\\nMedical accuracy: The explanation’s claim that “ECMO plus thrombectomy” is preferred over late systemic lysis overstates consensus; evidence is evolving and not yet definitive.\\n\\nMinimal fix: Either (1) change key to A and adjust explanation to align with ACLS guidance, or (2) explicitly state that the patient is in a specialized center with ECMO and thrombectomy immediately available and that guidelines here prioritize ECMO-PECPR strategy over systemic lysis.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible; also partly U for guideline nuance)\nVerdict on keyed answer: Not uniquely determinable\n\nKey stem clues: Massive saddle PE with shock then PEA arrest, 10 minutes of high-quality ACLS with ongoing CPR and no ROSC; CTA-confirmed PE; bedside echo with RV strain; no pericardial effusion; question asks “most appropriate next step.” Options contrast systemic thrombolysis during arrest vs VA‑ECMO + thrombectomy vs reduced-dose lysis vs stopping vs surgical embolectomy alone.\n\nMajor logical issue: Current ACLS/PE guidelines (AHA, ESC) explicitly state that for suspected/confirmed PE causing cardiac arrest, systemic thrombolysis during CPR is recommended/very reasonable. VA‑ECMO is recommended only where immediately available and usually as adjunct/bridge. Many centers cannot initiate ECMO promptly during arrest. Thus A (full-dose systemic alteplase during CPR) is strongly guideline-supported as the primary next step, whereas B is a reasonable but resource‑dependent advanced option. The stem gives no information about ECMO availability, making B not clearly superior to A. Hence at least A and B are defensible.\n\nMedical accuracy: The explanation’s claim that “ECMO plus thrombectomy” is preferred over late systemic lysis overstates consensus; evidence is evolving and not yet definitive.\n\nMinimal fix: Either (1) change key to A and adjust explanation to align with ACLS guidance, or (2) explicitly state that the patient is in a specialized center with ECMO and thrombectomy immediately available and that guidelines here prioritize ECMO-PECPR strategy over systemic lysis.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-006", "question": "A 38-year-old woman presents with progressive proximal muscle weakness over 6 weeks, difficulty climbing stairs, and new-onset dry cough. Exam shows 4/5 strength in hip flexors and shoulder abductors, Gottron papules over MCP joints, and a faint \"mechanic's hands\" rash. CK is 700 IU/L (mildly elevated). High-resolution CT shows bilateral peripheral ground-glass opacities and traction bronchiectasis in lower lobes. Pulmonary function tests show FVC 60% predicted, DLCO 35% predicted, and an FVC/DLCO ratio >1.6. ANA is positive 1:320 speckled. Which specific autoantibody, if present, would indicate the highest risk of rapidly progressive interstitial lung disease requiring aggressive early immunosuppression?", "options": ["Anti-Jo-1 (histidyl-tRNA synthetase)", "Anti-Mi-2", "Anti-MDA5", "Anti-SRP", "Anti-TIF1-γ"], "answer": "C", "answer_index": 2, "explanation": "Anti-MDA5 dermatomyositis is characteristically associated with rapidly progressive, often fatal ILD, even with only mild myositis or CK elevation, and warrants early aggressive combination immunosuppression. Anti-Jo-1 also associates with ILD but usually more indolent; anti-Mi-2 is linked to classic dermatomyositis with good prognosis; anti-SRP to necrotizing myopathy; anti-TIF1-γ to malignancy-associated dermatomyositis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 38-year-old woman with dermatomyositis features (Gottron papules, mechanic’s hands), mild CK elevation, but disproportionally severe and restrictive ILD: HRCT with bilateral peripheral ground-glass opacities and traction bronchiectasis; PFTs with markedly reduced DLCO (35%) and FVC/DLCO ratio >1.6, concerning for significant interstitial lung involvement. Question explicitly asks which autoantibody indicates highest risk of rapidly progressive ILD requiring aggressive early immunosuppression.\\nAnti-MDA5 (C) is well established to be associated with clinically amyopathic or hypomyopathic dermatomyositis and rapidly progressive, often fatal ILD, even with mild muscle involvement and modest CK — exactly mirroring the vignette and explanation. Anti-Jo-1 is also ILD-associated but usually with more indolent course; others (Mi-2, SRP, TIF1-γ) are linked to classic DM, necrotizing myopathy, or malignancy, not highest RP-ILD risk. Thus C is uniquely best and consistent with current rheumatology literature.\\nNo major medical inaccuracies identified; descriptors of PFT pattern and clinical association are appropriate.\\nMinimal fix: None required for validity; optionally add that myositis-specific antibody panel is being considered to clarify the teaching point further.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 38-year-old woman with dermatomyositis features (Gottron papules, mechanic’s hands), mild CK elevation, but disproportionally severe and restrictive ILD: HRCT with bilateral peripheral ground-glass opacities and traction bronchiectasis; PFTs with markedly reduced DLCO (35%) and FVC/DLCO ratio >1.6, concerning for significant interstitial lung involvement. Question explicitly asks which autoantibody indicates highest risk of rapidly progressive ILD requiring aggressive early immunosuppression.\nAnti-MDA5 (C) is well established to be associated with clinically amyopathic or hypomyopathic dermatomyositis and rapidly progressive, often fatal ILD, even with mild muscle involvement and modest CK — exactly mirroring the vignette and explanation. Anti-Jo-1 is also ILD-associated but usually with more indolent course; others (Mi-2, SRP, TIF1-γ) are linked to classic DM, necrotizing myopathy, or malignancy, not highest RP-ILD risk. Thus C is uniquely best and consistent with current rheumatology literature.\nNo major medical inaccuracies identified; descriptors of PFT pattern and clinical association are appropriate.\nMinimal fix: None required for validity; optionally add that myositis-specific antibody panel is being considered to clarify the teaching point further.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-007", "question": "A 72-year-old man with long-standing COPD (FEV1 35% predicted), chronic hypercapnia, and recent admission for an acute exacerbation requiring noninvasive ventilation is evaluated 3 weeks after discharge. He continues to have daytime somnolence and morning headaches despite resolution of wheeze and normalization of oxygenation on 2 L/min nasal cannula. ABG on his usual oxygen shows pH 7.37, PaCO2 58 mm Hg, PaO2 70 mm Hg, HCO3- 33 mEq/L. Overnight oximetry reveals sustained hypoventilation with episodic desaturations but no significant obstructive apneas. He is adherent to inhaled therapy and pulmonary rehab. What is the most appropriate next step in chronic management to improve mortality?", "options": ["Increase long-term oxygen therapy to maintain PaO2 >80 mm Hg", "Start nocturnal noninvasive ventilation with targeted normalization of PaCO2", "Add chronic low-dose oral prednisone", "Begin acetazolamide at night to stimulate ventilation", "Switch to high-flow nasal cannula at home during sleep"], "answer": "B", "answer_index": 1, "explanation": "In stable COPD with chronic hypercapnic respiratory failure, particularly after a hypercapnic exacerbation, nocturnal noninvasive ventilation targeting PaCO2 reduction reduces mortality and hospitalizations. Increasing oxygen can worsen hypercapnia; chronic steroids confer harm; acetazolamide has limited long-term data; home high-flow therapy improves comfort but lacks robust mortality benefit compared with NIV in this phenotype.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Severe COPD (FEV1 35%), chronic hypercapnia (PaCO2 58 with metabolic compensation), recent hypercapnic exacerbation requiring NIV, persistent daytime somnolence and morning headaches, overnight oximetry showing sustained hypoventilation with desaturations and no significant obstructive apneas, already on appropriate inhaled therapy and pulmonary rehab. These findings describe stable chronic hypercapnic COPD post-exacerbation, the phenotype shown in trials (e.g., HOT-HMV-type data) to benefit in mortality and hospitalizations from nocturnal NIV aimed at PaCO2 reduction.\\nOption analysis: A is inappropriate—higher oxygen targets can worsen hypercapnia and have no proven mortality benefit beyond standard LTOT thresholds. C (chronic oral prednisone) is harmful in stable COPD. D (acetazolamide) has limited and not mortality‑proven long‑term benefit. E (home HFNC) may improve comfort but lacks strong mortality evidence versus NIV in this phenotype. B directly matches guideline-concordant care and available evidence.\\nMain medical accuracy issue(s): None substantive; rationale is consistent with current evidence and guidelines.\\nMinimal fix: Clarify that his current oxygen meets standard LTOT indications and targets (e.g., specify prior resting PaO2 ≤55 mm Hg) to fully align with guideline wording, though it doesn’t affect the best answer.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Severe COPD (FEV1 35%), chronic hypercapnia (PaCO2 58 with metabolic compensation), recent hypercapnic exacerbation requiring NIV, persistent daytime somnolence and morning headaches, overnight oximetry showing sustained hypoventilation with desaturations and no significant obstructive apneas, already on appropriate inhaled therapy and pulmonary rehab. These findings describe stable chronic hypercapnic COPD post-exacerbation, the phenotype shown in trials (e.g., HOT-HMV-type data) to benefit in mortality and hospitalizations from nocturnal NIV aimed at PaCO2 reduction.\nOption analysis: A is inappropriate—higher oxygen targets can worsen hypercapnia and have no proven mortality benefit beyond standard LTOT thresholds. C (chronic oral prednisone) is harmful in stable COPD. D (acetazolamide) has limited and not mortality‑proven long‑term benefit. E (home HFNC) may improve comfort but lacks strong mortality evidence versus NIV in this phenotype. B directly matches guideline-concordant care and available evidence.\nMain medical accuracy issue(s): None substantive; rationale is consistent with current evidence and guidelines.\nMinimal fix: Clarify that his current oxygen meets standard LTOT indications and targets (e.g., specify prior resting PaO2 ≤55 mm Hg) to fully align with guideline wording, though it doesn’t affect the best answer.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-008", "question": "A 59-year-old man with a history of MI and paroxysmal atrial fibrillation presents with acute-onset right eye visual loss described as a \"curtain\" descending over 10 minutes, now partially improved. Exam reveals a right relative afferent pupillary defect and patchy visual field deficit; neurologic exam is otherwise normal. He takes apixaban 5 mg twice daily, metoprolol, and atorvastatin, and reports strict adherence. BP is 130/72 mm Hg. MRI brain with DWI is normal; MRA head/neck shows no large-vessel occlusion or significant carotid stenosis. Fundoscopic exam shows retinal whitening in the inferior arcade consistent with branch retinal artery occlusion (BRAO). Which management strategy is most appropriate regarding his antithrombotic regimen?", "options": ["Continue apixaban and add aspirin 81 mg daily indefinitely", "Switch apixaban to warfarin with target INR 2.5-3.5", "Continue apixaban at the same dose without change", "Increase apixaban dose to 10 mg twice daily for 1 month, then 5 mg twice daily", "Discontinue anticoagulation and use dual antiplatelet therapy for 90 days"], "answer": "C", "answer_index": 2, "explanation": "BRAO in an anticoagulated AF patient is treated as a small ischemic stroke; however, there is no high-level evidence that switching DOACs, adding chronic antiplatelet therapy, or using higher-dose anticoagulation improves outcomes over continuing appropriate-dose DOAC once adherence and dosing are confirmed. Adding aspirin increases bleeding risk without proven benefit; warfarin or dual antiplatelets are not superior for AF-related events when DOAC therapy is adequate.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Older man with AF on correctly dosed apixaban, good adherence, presents with BRAO (retinal whitening, transient “curtain,” RAPD, field deficit) and otherwise negative brain/MRA—treated as a small ischemic stroke/TIA without large-vessel target. No evidence of subtherapeutic dosing, nonadherence, or competing indication for antiplatelet therapy.\\nEvaluation of options: A (add aspirin indefinitely) is generally not recommended in AF patients on DOAC after ischemic stroke without another clear indication due to increased bleeding and lack of proven benefit. B (switch to warfarin, higher INR target) is not supported; DOACs are at least as effective and safer than warfarin for AF. D (temporary dose increase) is nonstandard and unstudied. E (stop anticoagulation and use DAPT) is inappropriate because AF is the dominant stroke mechanism; removing anticoagulation raises embolic risk.\\nThus, C (continue apixaban at the same dose) is the single best management strategy.\\nMain medical accuracy issues: None significant; the explanation correctly notes limited evidence for changing therapy after ischemic events on therapeutic DOAC.\\nMinimal fix: Clarify “no evidence of nonadherence or underdosing” in the stem to preempt alternative justifications for changing therapy.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Older man with AF on correctly dosed apixaban, good adherence, presents with BRAO (retinal whitening, transient “curtain,” RAPD, field deficit) and otherwise negative brain/MRA—treated as a small ischemic stroke/TIA without large-vessel target. No evidence of subtherapeutic dosing, nonadherence, or competing indication for antiplatelet therapy.\nEvaluation of options: A (add aspirin indefinitely) is generally not recommended in AF patients on DOAC after ischemic stroke without another clear indication due to increased bleeding and lack of proven benefit. B (switch to warfarin, higher INR target) is not supported; DOACs are at least as effective and safer than warfarin for AF. D (temporary dose increase) is nonstandard and unstudied. E (stop anticoagulation and use DAPT) is inappropriate because AF is the dominant stroke mechanism; removing anticoagulation raises embolic risk.\nThus, C (continue apixaban at the same dose) is the single best management strategy.\nMain medical accuracy issues: None significant; the explanation correctly notes limited evidence for changing therapy after ischemic events on therapeutic DOAC.\nMinimal fix: Clarify “no evidence of nonadherence or underdosing” in the stem to preempt alternative justifications for changing therapy.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-009", "question": "A 46-year-old man presents with sudden severe tearing chest pain radiating to the back. BP is 210/110 mm Hg in both arms, HR 112/min. CT angiography shows an acute Stanford type B aortic dissection starting distal to the left subclavian artery and extending to the infrarenal aorta with involvement of the origin of the left renal artery, but no signs of rupture or pericardial effusion. The left kidney is perfused via a narrowed true lumen; creatinine is 1.4 mg/dL (baseline 1.0). There is no limb ischemia, mesenteric ischemia, or refractory pain after initial IV beta-blocker and vasodilator therapy, and BP is controlled to 115/70 mm Hg. Which management strategy is most appropriate now?", "options": ["Immediate thoracic endovascular aortic repair (TEVAR) to prevent late aneurysmal degeneration", "Open surgical repair of the descending thoracic aorta due to renal artery involvement", "Strict medical therapy with anti-impulse control and serial imaging", "Prophylactic left renal artery stenting plus medical therapy", "Fenestration and true lumen expansion with balloon angioplasty"], "answer": "C", "answer_index": 2, "explanation": "Uncomplicated type B aortic dissection without rupture, malperfusion, refractory pain, or uncontrolled hypertension is managed initially with aggressive medical therapy and surveillance. Renal artery involvement without clinical malperfusion or progressive renal dysfunction does not mandate immediate TEVAR or intervention; endovascular repair is reserved for complicated cases or aneurysmal progression on follow-up imaging.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Acute Stanford type B dissection distal to left subclavian; no rupture or pericardial effusion; left kidney still perfused (narrowed true lumen) with only mild creatinine bump; no limb or mesenteric ischemia; no refractory pain after IV beta-blocker/vasodilator; blood pressure now well controlled at 115/70. These findings define an “uncomplicated” type B dissection.\\nIn current practice, first-line management of uncomplicated type B aortic dissection is optimal medical therapy (anti-impulse, BP and HR control) with serial imaging surveillance. Thus C is the single best answer.\\nOption A: TEVAR is not indicated solely to prevent possible late aneurysmal degeneration in a currently uncomplicated case.\\nOption B: Open repair is higher risk and reserved for select complicated situations; not indicated here.\\nOption D: Prophylactic renal stenting is unnecessary without malperfusion or worsening renal function.\\nOption E: Fenestration/angioplasty is used for dynamic malperfusion, which is specifically absent.\\nNo internal contradictions or underspecification; the classification of “uncomplicated” versus “complicated” is clear and uniquely supports the keyed answer.\\nMinimal fix: Add explicit phrase “he has no clinical or imaging signs of branch-vessel malperfusion” to further reinforce why endovascular interventions are not yet indicated.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Acute Stanford type B dissection distal to left subclavian; no rupture or pericardial effusion; left kidney still perfused (narrowed true lumen) with only mild creatinine bump; no limb or mesenteric ischemia; no refractory pain after IV beta-blocker/vasodilator; blood pressure now well controlled at 115/70. These findings define an “uncomplicated” type B dissection.\nIn current practice, first-line management of uncomplicated type B aortic dissection is optimal medical therapy (anti-impulse, BP and HR control) with serial imaging surveillance. Thus C is the single best answer.\nOption A: TEVAR is not indicated solely to prevent possible late aneurysmal degeneration in a currently uncomplicated case.\nOption B: Open repair is higher risk and reserved for select complicated situations; not indicated here.\nOption D: Prophylactic renal stenting is unnecessary without malperfusion or worsening renal function.\nOption E: Fenestration/angioplasty is used for dynamic malperfusion, which is specifically absent.\nNo internal contradictions or underspecification; the classification of “uncomplicated” versus “complicated” is clear and uniquely supports the keyed answer.\nMinimal fix: Add explicit phrase “he has no clinical or imaging signs of branch-vessel malperfusion” to further reinforce why endovascular interventions are not yet indicated.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-010", "question": "A 24-year-old man presents to the ED after being found confused and agitated. He reports taking an unknown \"research chemical\" for recreation. Vitals: T 40.1°C, HR 146/min, BP 178/104 mm Hg, RR 28/min, SpO2 96% RA. Exam shows mydriasis, diaphoresis, severe agitation with tremor, hyperreflexia, and inducible clonus, but no muscle rigidity. He is not taking prescription drugs and denies MAOI or SSRI use. Labs: Na 138, K 4.1, creatinine 1.0, CK 200 IU/L, normal LFTs. UDS is positive only for amphetamines. Despite high-dose benzodiazepines he remains agitated and hyperthermic. Which is the most appropriate next pharmacologic intervention?", "options": ["Intravenous dantrolene", "Intravenous cyproheptadine via crushed tablets", "Intravenous nitroprusside for blood pressure control alone", "Intravenous dexmedetomidine infusion", "Intravenous bromocriptine"], "answer": "D", "answer_index": 3, "explanation": "This is severe sympathomimetic (likely synthetic stimulant) toxicity with hyperthermia and agitation; there is hyperreflexia but the overall picture and isolated amphetamine screen favor stimulant rather than true serotonin syndrome. When benzodiazepines are insufficient, dexmedetomidine provides sympatholysis and sedation without worsening hyperthermia or respiratory drive as much as deep barbiturate or propofol sedation. Cyproheptadine and dantrolene target serotonin syndrome and NMS, respectively; bromocriptine is used in NMS and would exacerbate sympathomimetic effects.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young man with recreational “research chemical,” marked hyperthermia (40.1°C), tachycardia, hypertension, mydriasis, diaphoresis, agitation, tremor, hyperreflexia and inducible clonus, positive amphetamine screen, no serotonergic meds, normal CK, and failure of high‑dose benzodiazepines. These favor severe sympathomimetic toxicity from a synthetic stimulant rather than classic serotonin syndrome (usually serotonergic drug exposure; often more prominent clonus/rigidity, possible CK elevation). The question asks for next pharmacologic step when benzodiazepines fail.\\nD (IV dexmedetomidine) is defensible: centrally acting α2‑agonist providing sedation and sympatholysis, can reduce HR/BP and agitation without significant respiratory depression or worsening hyperthermia.\\nA (dantrolene) and E (bromocriptine) are NMS‑directed and not indicated; may delay appropriate care. B (cyproheptadine) targets serotonin syndrome, poorly supported by exposure history and labs. C (nitroprusside) treats BP but not agitation/hyperthermia and is not the primary next step.\\nNo major internal contradictions; single best answer exists and matches the key.\\nMain medical accuracy issues: Minor—hyperreflexia/clonus slightly point toward serotonin syndrome but not enough to override exposure pattern.\\nMinimal fix: Explicitly state no access to serotonergic agents or that similar cases have responded to sympatholytic agents to further distinguish from serotonin syndrome.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young man with recreational “research chemical,” marked hyperthermia (40.1°C), tachycardia, hypertension, mydriasis, diaphoresis, agitation, tremor, hyperreflexia and inducible clonus, positive amphetamine screen, no serotonergic meds, normal CK, and failure of high‑dose benzodiazepines. These favor severe sympathomimetic toxicity from a synthetic stimulant rather than classic serotonin syndrome (usually serotonergic drug exposure; often more prominent clonus/rigidity, possible CK elevation). The question asks for next pharmacologic step when benzodiazepines fail.\nD (IV dexmedetomidine) is defensible: centrally acting α2‑agonist providing sedation and sympatholysis, can reduce HR/BP and agitation without significant respiratory depression or worsening hyperthermia.\nA (dantrolene) and E (bromocriptine) are NMS‑directed and not indicated; may delay appropriate care. B (cyproheptadine) targets serotonin syndrome, poorly supported by exposure history and labs. C (nitroprusside) treats BP but not agitation/hyperthermia and is not the primary next step.\nNo major internal contradictions; single best answer exists and matches the key.\nMain medical accuracy issues: Minor—hyperreflexia/clonus slightly point toward serotonin syndrome but not enough to override exposure pattern.\nMinimal fix: Explicitly state no access to serotonergic agents or that similar cases have responded to sympatholytic agents to further distinguish from serotonin syndrome.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}]